Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
NEW YORK, Nov. 20, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Genocea Biosciences, Inc. (NASDAQ:GNCA) who purchased shares between May 5, 2017 and September 25, 2017. The action, which was filed in the U.S. District Court for the District of Massachusetts, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) the Company's finances were insufficient to support Phase 3 trials of GEN-003; (ii) accordingly, Genocea had overstated the prospects for GEN-003; and (iii) as a result of the foregoing, Genocea's public statements were materially false and misleading at all relevant times.
On September 25, 2017, Genocea disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug. The Company also announced that it was cutting 40% of its workforce.
Shareholders have until January 2, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/genocea-biosciences-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
